06/03/2026
A peer-reviewed, randomized controlled clinical trial published in Veterinary Sciences, a Q1 veterinary journal, found that dogsš with osteoarthritisš¦“š„ receiving just 40 mg of UC-IIĀ® (undenatured type II collagen) experienced improvements in mobility and comfort comparable to those seen in dogs receiving robenacoxib, a prescription anti-inflammatory medication.
After only 30 days, mobility improved by 32.7% in the UC-II group compared to 31.5% in the medication group, with no adverse effects reported in either group. One of the most surprising findings was how quickly UC-II worked, producing measurable benefits within just one month, faster than many previous UC-II studies have reported.
Unlike pain medicationsš that directly suppress inflammationš„, UC-II works through a process called oral tolerance, helping retrain the immune system to reduce cartilage-targeting inflammation and support long-term joint health.
Itās important to note that dogs with severe arthritis responded better to the prescription medication, while UC-II appeared most effective in dogs with mild to moderate osteoarthritis.
Thatās why Dr. Karen Becker included undenatured type II collagen (UC-II) in MOBILITY MATRIXā¢āa comprehensive, science-backed formula designed to support joints, muscles, cartilage, and connective tissue in both dogs and cats. By combining UC-II with other targeted mobility nutrients, MOBILITY MATRIXā¢ was created to help pets stay active, comfortable, and moving with ease.
šš¼Comment MATRIX to learn more about this science-backed mobility formula and weāll DM you the link.
